Silo Pharma (NASDAQ:SILO) vs. InMed Pharmaceuticals (NASDAQ:INM) Head-To-Head Contrast

InMed Pharmaceuticals (NASDAQ:INM) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.

Valuation & Earnings

This table compares InMed Pharmaceuticals and Silo Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94 million	0.92	-$8.16 million	($2.89)	-0.48
Silo Pharma	$70,000.00	53.13	-$4.23 million	($4.36)	-0.54

Silo Pharma has lower revenue, but higher earnings than InMed Pharmaceuticals. Silo Pharma is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for InMed Pharmaceuticals and Silo Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1	0	0	0	1.00
Silo Pharma	1	0	0	0	1.00

Profitability

This table compares InMed Pharmaceuticals and Silo Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Risk and Volatility

InMed Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Institutional & Insider Ownership

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

InMed Pharmaceuticals beats Silo Pharma on 7 of the 11 factors compared between the two stocks.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.